ZEO ScientifiX is playing a crucial role in expanding South Florida’s biotechnology sector with its focus on regenerative medicine and educational initiatives.
Genflow Biosciences has achieved significant milestones in its mid-year summary, including positive interim results from a clinical trial and collaborations that ensure non-dilutive funding. The company is strategically positioned for continued success in longevity research and animal health engagements.
ZEO ScientifiX has reported a remarkable increase in revenue, achieving a 124.6% growth for the three months ending April 30, 2026, primarily driven by its allogenic biologic products. This strong performance indicates a robust market demand and solidifies the company's position in the regenerative medicine field.
New to The Street Show #760 will air on Bloomberg Television, featuring insights from industry leaders in mergers and acquisitions, biotechnology, and media technology.
Protagenic Therapeutics has demonstrated the efficacy of PT00114 in reducing stress responses in rodent models, presenting a novel approach for treating stress-related disorders.
·2 min read·Protagenic Therapeutics, Inc | OTCQB:PTIX
AI/ML Innovations Inc. has secured a significant U.S. patent for advanced machine learning techniques in ECG analysis, enhancing its intellectual property portfolio and strengthening its position in the evolving health tech landscape.
Genflow Biosciences will attend the BIO International Convention in San Diego, California, highlighting its innovation in longevity research and gene therapies.
BioNxt Solutions Inc. has announced a non-brokered private placement, aiming to raise up to $2 million by issuing units at $0.33 each, as part of the Listed Issuer Financing exemption.